Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stuart J Pocock

Showing results (111-120 of 349) with videos related to

Pageof 35
Sort By:
JAMA Cardiology|September 21, 2022
Association of Empagliflozin Treatment With Albuminuria Levels in Patients With Heart Failure: A Secondary Analysis of EMPEROR-PooledJoão Pedro Ferreira, Faiez Zannad, Javed Butler, et al.
Journal of the American College of Cardiology|April 3, 2010
Long-term outcome of a routine versus selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome a meta-analysis of individual patient dataKeith A A Fox, Tim C Clayton, Peter Damman, et al.
Circulation|August 25, 2023
Blinded Withdrawal of Long-Term Randomized Treatment With Empagliflozin or Placebo in Patients With Heart FailureMilton Packer, Javed Butler, Cordula Zeller, et al.
European Journal of Heart Failure|May 23, 2022
Outcomes with empagliflozin in heart failure with preserved ejection fraction using DELIVER-like endpoint definitionsStefan D Anker, Tariq Jamal Siddiqi, Gerasimos Filippatos, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|September 29, 2018
Impact of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with heart failure and left-ventricular systolic dysfunction: an individual patient-level meta-analysis of three randomized-controlled trialsXavier Rossello, Cono Ariti, Stuart J Pocock, et al.
European Heart Journal|June 10, 2022
Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-PooledJoão Pedro Ferreira, Faiez Zannad, Javed Butler, et al.
Journal of the American College of Cardiology|September 14, 2019
In-Hospital Coronary Revascularization Rates and Post-Discharge Mortality Risk in Non-ST-Segment Elevation Acute Coronary SyndromeHéctor Bueno, Xavier Rossello, Stuart J Pocock, et al.
European Heart Journal|February 2, 2010
Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trialMichel Komajda, John J V McMurray, Henning Beck-Nielsen, et al.
International Journal of Surgery (London, England)|July 22, 2014
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaborationJan P Vandenbroucke, Erik von Elm, Douglas G Altman, et al.
JAMA|May 3, 2007
Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized TrialAlexandre Mebazaa, Markku S Nieminen, Milton Packer, et al.
Pageof 35

Showing results (111-120 of 349) with videos related to

Sort By:
Pageof 35
JAMA Cardiology|September 21, 2022
Association of Empagliflozin Treatment With Albuminuria Levels in Patients With Heart Failure: A Secondary Analysis of EMPEROR-PooledJoão Pedro Ferreira, Faiez Zannad, Javed Butler, et al.
Journal of the American College of Cardiology|April 3, 2010
Long-term outcome of a routine versus selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome a meta-analysis of individual patient dataKeith A A Fox, Tim C Clayton, Peter Damman, et al.
Circulation|August 25, 2023
Blinded Withdrawal of Long-Term Randomized Treatment With Empagliflozin or Placebo in Patients With Heart FailureMilton Packer, Javed Butler, Cordula Zeller, et al.
European Journal of Heart Failure|May 23, 2022
Outcomes with empagliflozin in heart failure with preserved ejection fraction using DELIVER-like endpoint definitionsStefan D Anker, Tariq Jamal Siddiqi, Gerasimos Filippatos, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|September 29, 2018
Impact of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with heart failure and left-ventricular systolic dysfunction: an individual patient-level meta-analysis of three randomized-controlled trialsXavier Rossello, Cono Ariti, Stuart J Pocock, et al.
European Heart Journal|June 10, 2022
Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-PooledJoão Pedro Ferreira, Faiez Zannad, Javed Butler, et al.
Journal of the American College of Cardiology|September 14, 2019
In-Hospital Coronary Revascularization Rates and Post-Discharge Mortality Risk in Non-ST-Segment Elevation Acute Coronary SyndromeHéctor Bueno, Xavier Rossello, Stuart J Pocock, et al.
European Heart Journal|February 2, 2010
Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trialMichel Komajda, John J V McMurray, Henning Beck-Nielsen, et al.
International Journal of Surgery (London, England)|July 22, 2014
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaborationJan P Vandenbroucke, Erik von Elm, Douglas G Altman, et al.
JAMA|May 3, 2007
Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized TrialAlexandre Mebazaa, Markku S Nieminen, Milton Packer, et al.
Pageof 35